PeptidePicker
CognitiveResearch

P21

Also known as: P021 · CNTF-derived peptide

A neurogenic peptide derived from CNTF that promotes hippocampal neurogenesis and clears amyloid plaques, targeting Alzheimer's and TBI recovery.

Dr. Sarah Mitchell

Reviewed by Dr. Sarah Mitchell, PharmD, BCPS

Lead Researcher · 12+ years in peptide therapeutics

Half-Life

~2–4 hours

Typical Dose

500–1000 mcg

Administration

Subcutaneous injection

Mechanism of Action

Mimics CNTF neurotrophic activity to stimulate neural stem cell differentiation while inhibiting tau hyperphosphorylation and amyloid aggregation.

Key Research Areas

nootropicneurogenesisAlzheimer'scognitive

Frequently Asked Questions

What is P21?
A neurogenic peptide derived from CNTF that promotes hippocampal neurogenesis and clears amyloid plaques, targeting Alzheimer's and TBI recovery.
How does P21 work?
Mimics CNTF neurotrophic activity to stimulate neural stem cell differentiation while inhibiting tau hyperphosphorylation and amyloid aggregation.
What is the recommended dosage for P21?
The typical research dosage is 500–1000 mcg, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of P21?
The half-life of P21 is approximately ~2–4 hours. This affects dosing frequency and timing in research protocols.
Is P21 FDA approved?
P21 is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.

Research Disclaimer

The information provided about P21 is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.

Related Peptides in Cognitive